Cargando…
Development of Coronavirus Treatments Using Neutralizing Antibodies
The Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, was first reported in December 2019 in Wuhan, Hubei province, China. This virus has led to 61.8 million cases worldwide being reported as of December 1st, 2020. Currently, there are no definite approved therapies en...
Autores principales: | Fouladirad, Saman, Bach, Horacio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828509/ https://www.ncbi.nlm.nih.gov/pubmed/33451069 http://dx.doi.org/10.3390/microorganisms9010165 |
Ejemplares similares
-
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks
por: Wooding, Denise J., et al.
Publicado: (2020) -
Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers
por: Landais, Elise, et al.
Publicado: (2018) -
Coronaviruses pandemics: Can neutralizing antibodies help?
por: Tong, Phuoc-Bao-Viet, et al.
Publicado: (2020) -
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
por: Chen, Yanjia, et al.
Publicado: (2022) -
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2
por: Zhou, Guangyu, et al.
Publicado: (2020)